SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan Rogel Cancer Center
Study ID
NCT07096999
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Castration-Resistant Prostate Carcinoma

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Non-Interventional Study — OTHER
    Non-interventional study

Study Details

This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy

Key Dates

First listed
Jul 31, 2025
Start date
Jan 23, 2025
Status verified
Jul 2025
Primary completion
Jan 23, 2031
Completion
Jan 23, 2031

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Observational
    Patients receive standard care Pluvicto and undergo Lu-177 SPECT/CT scans on study. Patients may also undergo optional 99mTc-SC SPECT/CT scan for bone marrow dosimetry prior to cycle 1. In addition, patients have their medical records reviewed on study.

Primary Outcome Measure

Response and toxicity following 177Lu-RLT [ Time Frame: Up to 4 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Michigan Comprehensive Cancer CenterAnn ArborMichigan48109
James Pool
[email protected]
734-615-7391
Yuni K. Dewaraja (PRINCIPAL_INVESTIGATOR)

Find similar trials in Ann Arbor, MI

By research site
University of Michigan Comprehensive Cancer Center· Ann Arbor, MI

Related Studies